Collaboration and Innovation Position Precision BioLogic as a Leader in Hemostasis Diagnostics

Precision BioLogic: A Trailblazer in Hemostasis Diagnostics

Precision BioLogic Inc., a prominent player in the field of hemostasis diagnostic solutions, has significantly enhanced its reputation through strategic collaborations with its subsidiaries, Affinity Biologicals and George King Bio-Medical. Together, they are garnering attention from clinicians and researchers in the field of hemostasis diagnostics around the world.

The company recently made headlines when it announced an expansion of the applications for its innovative CRYOcheck™ Chromogenic Factor VIII assay. This announcement comes at an opportune moment, as new treatments for hemophilia, including Mim8—a next-generation bispecific antibody—are on the brink of approval following Nova Nordisk's submission to the U.S. FDA.

Paul Empey, President and CEO of Precision BioLogic, elaborated on this momentum at the ISTH 2026 conference held in Paris earlier this summer, stating that the booth attracted numerous inquiries about their bovine Chromogenic Factor VIII. This product is gaining traction for its accuracy in measuring factor VIII levels, especially in the context of extended half-life FVIII replacement therapies and emerging FVIIIa mimetic bispecific antibodies.

"There is an increasing demand for chromogenic assays, and our commitment is to ensure coagulation laboratories can provide precise and reliable results," Empey said, highlighting the importance of their contributions to the field.

The company’s research was also prominently featured at ISTH through the presentation of significant scientific posters that delve into new findings relevant to hemostasis diagnostics. Topics included automated lupus anticoagulant assays resilient against anticoagulant drugs like DOACs and oral FXI inhibitors, as well as the impact of heat-stable Factor VIII mimetics on inhibitor titers. These findings are now accessible on the Precision BioLogic website.

Following the ISTH, the team showcased their innovative manufacturing capabilities at the ADLM 2026 in Anaheim, CA, reflecting the adaptability and technical proficiency of Affinity Biologicals. They then continued their schedule at the NBDF's Bleeding Disorders Conference in Orlando, FL. This event was a crucial platform for George King Bio-Medical to engage with healthcare professionals, advocate for plasma donation, and discuss its critical role in advancing research and treatment strategies for bleeding disorders.

As the summer of 2026 draws to a close, the synergy between Precision BioLogic, Affinity Biologicals, and George King Bio-Medical is fostering a wave of continuity in the global hemophilia community. Their collaboration aims to provide robust products, responsive services, and significant innovations for healthcare providers around the world.

About Precision BioLogic

Founded in Nova Scotia, Precision BioLogic specializes in developing, manufacturing, and marketing a comprehensive line of CRYOcheck™ products that help medical professionals diagnose coagulation disorders. The acquisitions of Affinity Biologicals in November 2018 and George King Bio-Medical in October 2025 have fortified their expertise in thrombosis and hemostasis, broadening their research and diagnostic capabilities. More information can be found on their website at www.precisionbiologic.com.